HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Amgen’s Prolia/Xgeva Original Sales Close To $100m, mAbxience In Phase III
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
